Skip to main content

Day: October 13, 2022

P10 Completes Acquisition of Western Technology Investment, Market Leader in Venture Debt

DALLAS, Oct. 13, 2022 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX) (“P10” or the “Company”), a leading private markets solutions provider, today announced it has completed its previously announced acquisition of all of the outstanding membership interests of Westech Investment Advisors LLC, a California limited liability company (“WTI”) (the “Acquisition” or “Transaction”) through its subsidiary, P10 Intermediate Holdings LLC, for a purchase price consisting of $97,000,008 in cash and an aggregate of 3,916,666 membership units of P10 Intermediate Holdings, LLC, which can be exchanged into 3,916,666 shares of P10 common stock, following applicable restrictive periods. P10 expects WTI to contribute more than $12.5 million in Adjusted EBITDA in its first full year following the closing. Moreover, assuming current and historic deployment...

Continue reading

Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022

Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods®Technology Notice of Patent Allowance in Japan containing broad claims pertaining to treating Depression using the InFoods® TechnologyIRVINE, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million for the same period in the previous year, a 30% increase. Net loss for the quarter ended August 31, 2022 was $2.0 million, or $0.16 per share, compared to a net loss of $1.5 million, or $0.12 per share for the same period in the previous year. Sales, general and administrative expenses for the three months ended August 31, 2022 were $1.65...

Continue reading

Canoe EIT Income Fund Announces October 2022 Distribution

CALGARY, Alberta, Oct. 13, 2022 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (the “Fund”) (TSX – EIT.UN) announces the October 2022 distribution of $0.10 per unit. The distribution will be paid on November 15, 2022 to unitholders of record on October 21, 2022. The ex-distribution date for this distribution is October 20, 2022. About Canoe EIT Income FundCanoe EIT Income Fund is one of Canada’s largest closed-end investment funds, designed to maximize monthly distributions and capital appreciation by investing in a broadly diversified portfolio of high quality securities. The Fund is listed on the TSX under the symbols EIT.UN, EIT.PR.A and EIT.PR.B, and is actively managed by Robert Taylor, Senior Vice President and Chief Investment Officer, Canoe Financial. About Canoe Financial Canoe Financial is one of Canada’s fastest growing...

Continue reading

Enliven Therapeutics and Imara Announce Merger Agreement

Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host conference call today at 5:00 p.m. E.T.Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc....

Continue reading

Credicorp Ltd.: Credicorp’s “3Q22 quiet period”

Lima, Oct. 13, 2022 (GLOBE NEWSWIRE) — Lima, PERU, October 13th, 2022 — Credicorp (NYSE: BAP) announces that in accordance with its corporate disclosure policies and to prevent any leaks of financial results and ensure fairness, the Company will start the quiet period for 3Q22’s earnings release on October 20th. This period will end on the date of the release, November 3rd. During the quiet period, the Company will not disclose any financial, comment on financial results, or respond to related questions.About Credicorp Credicorp Ltd. (NYSE: BAP) is the leading financial services holding company in Peru with presence in Chile, Colombia and Bolivia. Credicorp has a diversified business portfolio organized into four lines of business: Universal Banking, through Banco de Credito del Peru – BCP and Banco de Credito de Bolivia;...

Continue reading

Oil-Dri Announces Record Sales for the Fourth Quarter and Fiscal Year 2022

CHICAGO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its fourth quarter and fiscal year 2022.  Fourth Quarter Year to Date(in thousands, except per share amounts) Ended July 31, Ended July 31,  2022 2021 Change 2022 2021 ChangeConsolidated Results            Net Sales $93,158 $78,129 19 % $348,589 $304,981 14 %Net Income Attributable to Oil-Dri $5,196 $603 762 % $5,674 $11,113 (49 )%Net Income Attributable to Oil-Dri Excluding Goodwill Impairment† N/A N/A N/A $10,136 $11,113 (9 )%Earnings per Common Diluted Share $0.77 $0.08 863 % $0.81 $1.57 (48 )%Earnings per Common Diluted Share Excluding Goodwill Impairment† N/A N/A N/A $1.46 $1.57 (7 )%Business to Business            Net Sales $32,229 $26,409 22 % $113,379 $97,138 17 %Segment...

Continue reading

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months. As part of its late-cycle review, the FDA has requested that the Company update its proposed Risk Evaluation Mitigation Strategy (REMS) to include liver monitoring for sparsentan consistent with certain other approved products in the endothelin receptor antagonist class. The Company anticipates submitting...

Continue reading

Duolingo to Announce Second Quarter Results on Thursday, November 10, 2022

PITTSBURGH, Oct. 13, 2022 (GLOBE NEWSWIRE) — Duolingo, Inc. (Nasdaq: DUOL), the world’s leading mobile learning platform, will announce its results for the third quarter ending September 30, 2022, following the close of the U.S. market on Thursday, November 10, 2022. The Company will host a video webcast at 5:30 p.m. ET on that day. The live video webcast will be accessible to the public through Duolingo’s Investors Relations website at https://investors.duolingo.com. A replay of the event will be available two hours after the live event and archived for one year. About DuolingoDuolingo is the leading mobile learning platform globally. Its flagship app has organically become the world’s most popular way to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store....

Continue reading

Stantec to Release Third Quarter 2022 Results on November 10, 2022, and Host Webcast and Conference Call on November 11, 2022

EDMONTON, Alberta, Oct. 13, 2022 (GLOBE NEWSWIRE) — TSX,NYSE: STN Stantec, a global leader in sustainable design engineering, will release its third quarter 2022 financial results after markets close on Thursday, November 10, 2022. On Friday, November 11, 2022, at 7:00 AM Mountain Time (9:00 AM Eastern Time), Stantec will hold a conference call for management to discuss the Company’s performance. To listen to the webcast and view the slide presentation, please join here. If you are an analyst and would like to participate in the Q&A, please register here. The conference call and slideshow presentation will be accessible on the Investors section of stantec.com. About Stantec Communities are fundamental. Whether around the corner or across the globe, they provide a foundation, a sense of place and of belonging. That’s...

Continue reading

Sanofi: Information concerning the total number of voting rights and shares – September 2022

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 54, rue La Boétie – 75008 Paris – FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844Date   Total number of issued shares   Number of real voting rights(excluding treasury shares) Theoretical number of voting rights (including treasury shares)*September 30, 2022 1,267,479,766 1,411,899,228 1,425,326,874* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers. This...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.